Autolus Therapeutics (NASDAQ:AUTL) Trading Down 7% - Here's Why

Key Points

• AUTL shares fell 7% to about $2.17 despite Autolus reporting better-than-expected second-quarter results, including a loss of $0.15 per share versus expectations of $0.21 and revenue of $45.69 million versus $38.56 million.
• Management raised its AUCATZYL outlook, signaling commercial momentum, but the company remains deeply unprofitable, with a negative net margin of 311.98% and negative return on equity of 128.59%.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $8.75, although ratings range from “Strong Buy” to “Sell,” reflecting ongoing execution and funding risks.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) shares fell 7% during trading on Wednesday . The company traded as low as $2.19 and last traded at $2.1680. Approximately 714,216 shares changed hands during mid-day trading, a decline of 59% from the average session volume of 1,727,052 shares. The stock had previously closed at $2.33.

Trending Headlines about Autolus Therapeutics

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: Q2 results exceeded expectations: Autolus reported a loss of $0.15 per share, better than the $0.21 loss analysts expected. Revenue reached $45.69 million versus the $38.56 million consensus estimate, providing evidence of better-than-anticipated commercial progress. Autolus Second-Quarter 2026 Results
• Positive Sentiment: Higher AUCATZYL guidance signals launch momentum: Management raised its outlook for AUCATZYL, helping reinforce expectations for stronger sales growth as the therapy’s commercial rollout progresses. The guidance increase was identified as a key reason shares rose following the results. Autolus Shares and AUCATZYL Guidance
• Neutral Sentiment: Short-interest data provides no usable signal: The report lists short interest at zero shares on both July 27 and August 11, with a zero-day days-to-cover ratio. Because the figures produce an invalid percentage change and appear inconsistent with a normally reported short-interest dataset, they do not meaningfully indicate changing bearish positioning.
• Negative Sentiment: Autolus remains unprofitable: Despite beating estimates, the company continues to post losses, with a reported negative net margin of 311.98% and negative return on equity of 128.59%. Continued cash needs and execution risks remain important concerns as the company invests in AUCATZYL’s commercialization. Autolus Q2 2026 Earnings Call Transcript

Wall Street Analyst Weigh In

Several brokerages recently weighed in on AUTL. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Weiss Ratings cut shares of Autolus Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, July 31st. Wall Street Zen raised shares of Autolus Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday. Finally, Jefferies Financial Group upgraded shares of Autolus Therapeutics to a "strong-buy" rating in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $8.75.

Autolus Therapeutics Stock Performance

The stock has a market capitalization of $573.57 million, a P/E ratio of -1.98 and a beta of 2.07. The business has a 50-day moving average price of $1.61 and a 200 day moving average price of $1.55.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.06. Autolus Therapeutics had a negative return on equity of 128.59% and a negative net margin of 311.98%.The company had revenue of $45.69 million during the quarter, compared to analyst estimates of $38.56 million. As a group, research analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Several large investors have recently modified their holdings of the stock. GAMMA Investing LLC increased its stake in Autolus Therapeutics by 115.6% during the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company's stock valued at $25,000 after purchasing an additional 8,309 shares in the last quarter. Independent Advisor Alliance bought a new position in shares of Autolus Therapeutics in the fourth quarter worth approximately $28,000. Marex Group plc purchased a new stake in shares of Autolus Therapeutics during the second quarter valued at approximately $28,000. Waverly Advisors LLC purchased a new stake in shares of Autolus Therapeutics during the first quarter valued at approximately $37,000. Finally, SmartHarvest Portfolios LLC bought a new stake in shares of Autolus Therapeutics during the fourth quarter valued at approximately $43,000. Hedge funds and other institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source